Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.72 |
| ▸ | BACE1 | P56817 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | IDE | P14735 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PNLIP | P16233 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212077 | 0.93 | ALOX5 (0.87) | ALOX5PTGS1NR1H4BACE1MAPT | |
| SCHEMBL3434917 | 0.86 | NR1H4 (0.78) | ALOX5PTGS1NR1H4BACE1MAPT | |
| (R)-Sargachromenol SCHEMBL10301178 | 0.85 | NR1H4 (1.00) | ALOX5PTGS1NR1H4BACE1APP | |
| Tuberatolide B SCHEMBL38651892 | 0.81 | NR1H4 (1.00) | ALOX5PTGS1NR1H4BACE1MAPT | |
| SCHEMBL10536246 | 0.80 | ALOX5 (0.66) | ALOX5PTGS1NR1H4BACE1MAPT | |
| Cordiachromene A SCHEMBL16666262 | 0.79 | PTGS1 (0.68) | ALOX5PTGS1NR1H4BACE1MAPT | |
| Cordiachromene A SCHEMBL16666288 | 0.79 | PTGS1 (0.68) | ALOX5PTGS1NR1H4BACE1MAPT | |
| Cordiachromene A SCHEMBL9356402 | 0.79 | PTGS1 (0.68) | ALOX5PTGS1NR1H4BACE1MAPT | |
| SCHEMBL14283918 | 0.77 | ALOX5 (0.62) | ALOX5PTGS1NR1H4BACE1MAPT | |
| SCHEMBL10536271 | 0.75 | PTGS1 (0.60) | ALOX5PTGS1NR1H4BACE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656178-A1 | COSMETIC USE OF ATRACTYLODES LANCEA ROOT EXTRACT | Provital, S.A. (ES) | 2025-12-03 | — | — | EP | disclosed |
| US-20150150770-A1 | METHODS OF TREATING SKIN | TRACIE MARTYN INTERNATIONAL INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140155961-A1 | METHODS OF TREATING SKIN | Tracie Martyn International, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20100272790-A1 | Methods of Treating Skin | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776915-B2 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
| US-20020192305-A1 | Inflammatory mediation obtained from atractylodes lancea | MONSANTO COMPANY | 2002-12-19 | — | — | US | disclosed |
| CN-1362881-A | Inflammatory mediation obtained from atractylodes lancea | PHARMACIA CO (US) | 2002-08-07 | — | — | CN | disclosed |
| WO-2000056348-A9 | INFLAMMATORY MEDIATION OBTAINED FROM ATRACTYLODES LANCEA | PHARMACIA CORP (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-1171142-A1 | INFLAMMATORY MEDIATION OBTAINED FROM ATRACTYLODES LANCEA | MONSANTO COMPANY (US) | 2002-01-16 | — | — | EP | disclosed |
| US-20010006686-A1 | INFLAMMATORY MEDIATION OBTAINED FROM ATRACTYLODES LANCEA | MONSANTO COMPANY | 2001-07-05 | — | — | US | disclosed |
| WO-2000056348-A1 | INFLAMMATORY MEDIATION OBTAINED FROM ATRACTYLODES LANCEA | PHARMACIA CORPORATION (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155961-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | ALOX5 89/4885PTGS1 2158/4885NR1H4 3403/4885 |
| US-20100272790-A1 | Methods of Treating Skin | CUTA, LIPA, DLAT | ALOX5 89/4885PTGS1 2158/4885NR1H4 3403/4885 |
| US-20150150770-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | ALOX5 89/4885PTGS1 2158/4885NR1H4 3403/4885 |
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | ALOX5 133/4885PTGS1 1349/4885NR1H4 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.